Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone hemisuccinate
Drug ID BADD_D01435
Description A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
Indications and Usage Adjunctive therapy for short-term administration in rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB14644
KEGG ID D05000
MeSH ID D008776
PubChem ID 16923
TTD Drug ID Not Available
NDC Product Code 57582-012; 24002-0015; 82298-109; 22552-0024; 52128-152
Synonyms Methylprednisolone Hemisuccinate | Hemisuccinate, Methylprednisolone | Methylprednisolone Succinate | Succinate, Methylprednisolone | Urbason-Soluble | UrbasonSoluble | Solu-Medrol | Solumedrol | A-MethaPred | Methylprednisolone Sodium Succinate | Sodium Succinate, Methylprednisolone | Methylprednisolone Hemisuccinate Monosodium Salt | 6 alpha-Methylprednisolone Sodium Hemisuccinate | Methylprednisolone Sodium Hemisuccinate | Sodium Hemisuccinate, Methylprednisolone
Chemical Information
Molecular Formula C26H34O8
CAS Registry Number 2921-57-5
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperpyrexia08.05.02.0020.034973%Not Available
Hypersensitivity10.01.03.0030.258799%
Hypertension24.08.02.0010.174864%
Hypertensive crisis24.08.01.0010.020984%Not Available
Hyperthermia12.05.01.002; 08.05.01.0010.013989%Not Available
Hypoaesthesia17.02.06.0230.076940%Not Available
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypokalaemia14.05.03.0020.048962%
Hyponatraemia14.05.04.002--
Hypotension24.06.03.0020.251805%
Hypothermia12.05.03.001; 08.05.01.0030.034973%
Hypovolaemic shock24.06.02.0170.013989%Not Available
Hypoxia22.02.02.0030.069946%
Idiopathic pulmonary fibrosis22.01.02.014; 10.02.01.0340.020071%Not Available
Impaired healing08.03.02.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Infection11.01.08.0020.014597%Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.0020.188853%
Interstitial lung disease22.01.02.003; 10.02.01.0330.055957%Not Available
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.0020.020984%Not Available
Irritability19.04.02.013; 08.01.03.0110.048962%
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.027978%Not Available
Laceration23.03.11.004; 12.01.06.0060.034973%Not Available
Lacrimation increased06.08.02.0040.020984%
Lactic acidosis14.01.01.002--Not Available
Laryngeal oedema10.01.05.003; 23.04.01.005; 22.04.02.0010.013989%
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 17 Pages